Abstract

A polypeptide fragment B (MP-B) has an amino acid sequence shown in SEQ ID NO: 1, in which an amino acid Xaa at position 10 is Arg, Phe, Glu, Thr, or absent, an amino acid Xaa at position 16 is Asn, Val, Leu, Gly, or absent, and an amino acid Xaa at position 25 is Ser, Glu, Met, Arg, or absent. The MP-B can significantly improve the colonic pathologic morphology and decrease a colonic histopathologic score and an expression level of colonic interferon-γ (IFN-γ) in an inflammatory bowel disease (IBD) mouse model, and shows the ability to interfere with the occurrence of IBD in mice.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 33/18 - PeptidesProtein hydrolysates

Abstract

A polypeptide fragment C (MP-C) has an amino acid sequence shown in SEQ ID NO: 1, in which an amino acid Xaa at position 9 is Tyr, Val, Gly, Ser, or Gln, an amino acid Xaa at position 20 is Ser, Gln, Glu, or Tyr, an amino acid Xaa at position 30 is Asn, Thr, Ser, Pro, or Leu, and an amino acid Xaa at position 42 is Gly, Arg, Met, or absent. The MP-C can significantly improve the colonic pathologic morphology and decrease a disease activity index (DAI) and a colonic histopathologic score in an inflammatory bowel disease (IBD) mouse model, and shows the ability to interfere with the occurrence of IBD in mice.

IPC Classes  ?

• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

A polypeptide fragment D (MP-D) has an amino acid sequence shown in SEQ ID NO: 1, in which an amino acid Xaa at position 9 is Tyr, Val, Gly, Ser, Gln, or absent, an amino acid Xaa at position 20 is Ser, Gln, Glu, Tyr, Arg, or absent, and an amino acid Xaa at position 25 is Asn, Thr, Ser, Pro, Leu, or absent. The MP-D can significantly improve the colonic pathologic morphology and decrease a colonic histopathologic score and an expression level of colonic interferon-γ (IFN-γ) in an inflammatory bowel disease (IBD) mouse model, and shows the ability to interfere with the occurrence of IBD in mice.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

The present invention relates to the technical field of biomedicine, and specifically relates to a polypeptide fragment B and an application thereof, the polypeptide fragment B having the amino acid sequence shown in SEQ ID NO. 1, wherein the amino acid Xaa at position 10 is Arg, Phe, Glu or Thr, or is not present, the amino acid Xaa at position 16 is Asn, Val, Leu or Gly, or is not present, and the amino acid Xaa at position 25 is Ser, Glu, Met or Arg, or is not present. MP-B significantly improves the colon pathological morphology of an IBD mouse model, reduces colon histopathological scores and colon interferon-gamma expression amounts, and has the ability to interfere with the occurrence of inflammatory bowel disease in mice.

IPC Classes  ?

• C07K 14/335 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Lactobacillus (G)
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A23L 33/18 - PeptidesProtein hydrolysates

Abstract

The present invention relates to the technical field of biomedicine, and specifically relates to a polypeptide fragment C and an application thereof, the polypeptide fragment C having the amino acid sequence shown in SEQ ID NO. 1, wherein the amino acid Xaa at position 9 is Tyr, Val, Gly, Ser or Gln, the amino acid Xaa at position 20 is Ser, Gln, Glu or Tyr, the amino acid Xaa at position 30 is Asn, Thr, Ser, Pro or Leu, and the amino acid Xaa at position 42 is Gly, Arg or Met, or is not present. MP-C significantly improves the colon pathological morphology of an IBD mouse model, reduces disease activity indices and colon histopathological scores, and has the ability to interfere with the occurrence of inflammatory bowel disease in mice.

IPC Classes  ?

• C07K 14/335 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Lactobacillus (G)
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A23L 33/18 - PeptidesProtein hydrolysates

Abstract

The present invention relates to the technical field of biomedicine, and specifically relates to a polypeptide fragment D and an application thereof, the polypeptide fragment D having the amino acid sequence shown in SEQ ID NO. 1, wherein the amino acid Xaa at position 9 is Tyr, Val, Gly, Ser or Gln, or is not present, the amino acid Xaa at position 20 is Ser, Gln, Glu, Tyr or Arg, or is not present, and the amino acid Xaa at position 25 is Asn, Thr, Ser, Pro or Leu, or is not present. MP-D significantly improves the colon pathological morphology of an IBD mouse model, reduces colon histopathological scores and colon interferon-gamma expression amounts, and has the ability to interfere with the occurrence of inflammatory bowel disease in mice.

IPC Classes  ?

• C07K 14/335 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Lactobacillus (G)
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A23L 33/18 - PeptidesProtein hydrolysates